Welcome to our dedicated page for Apyx Medical Corporation news (Ticker: APYX), a resource for investors and traders seeking the latest updates and insights on Apyx Medical Corporation stock.
Overview
Apyx Medical Corporation is an energy technology company distinguished by its innovative plasma‐based medical devices utilized in both the cosmetic and hospital surgical markets. The company develops, manufactures, and markets advanced energy solutions that provide surgeons with precise and controlled heat applications, addressing both tissue cutting and coagulation needs. Operating under a dual-segment framework, its services are divided into Advanced Energy and Original Equipment Manufacturing (OEM), each contributing uniquely to its overall market presence. Its technology portfolio, including the Renuvion and J-Plasma systems, leverages patented helium plasma technology and specialized waveforms, enabling high-performance surgical applications and reducing unintended tissue trauma.
Advanced Energy Solutions
The Advanced Energy segment of Apyx Medical Corporation centers on its core plasma-based technologies. These systems are designed to offer enhanced control during surgical and cosmetic procedures by delivering precise energy in the form of helium plasma. Surgeons in both cosmetic and hospital surgical environments benefit from these technologies through improved accuracy and reduced collateral tissue damage. The company has strategically engineered its products to support various applications, ranging from body contouring and soft tissue ablation to coagulation, positioning itself as a key player in the energy technology medical device industry. The integration of over 90 clinical documents demonstrates a consistent level of clinical validation and supports the efficacy and safety profiles of these advanced energy solutions.
OEM Manufacturing Capabilities
In addition to its Advanced Energy segment, Apyx Medical Corporation is also prominently involved in the Original Equipment Manufacturing (OEM) sector. By designing and producing electrosurgical generators and related accessories, the company not only markets its own devices but also partners with other leading medical device manufacturers. This dual approach enables Apyx to extend its technological expertise to a wider market, enhancing its revenue streams while fostering innovation across the medical device landscape. The OEM segment benefits from the company’s deep experience in developing unique waveform technologies and precision energy delivery, making it an indispensable partner in the creation of next-generation medical devices.
Technology and Innovation
The technological backbone of Apyx Medical Corporation lies in its pursuit of innovation within the energy technology sector. The company’s patented plasma-based systems, marketed under brands such as Renuvion and J-Plasma, are at the forefront of modern electrosurgical applications. These systems enable controlled energy delivery, allowing surgeons to work with enhanced precision and significantly reducing the risk of unintended tissue trauma. The controlled heat delivery mechanisms are particularly critical in cosmetic and reconstructive procedures, where precision is paramount. The company’s considerable investment in research and clinical studies underpins its commitment to technological excellence, providing a robust foundation for continuous improvements and product enhancements.
Market Position and Industry Impact
Apyx Medical Corporation occupies a distinct position within the broader energy technology and medical device sectors. With a reputation for developing innovative plasma-based surgical solutions, the company serves a diverse clientele including plastic surgeons, facial plastic surgeons, and cosmetic physicians. Its technologies are integral in procedures that demand high precision and minimal invasiveness. The advanced energy solutions not only address existing surgical challenges but also set new standards in terms of device performance and patient safety. This strategic positioning is further reinforced by the company’s OEM collaborations, which enable it to disseminate its expertise across various facets of the medical device industry. While navigating a competitive environment that includes both established and emerging players, Apyx distinguishes itself through its commitment to refining technological innovations and adhering to rigorous clinical standards.
Operational Excellence and Quality Assurance
Operational excellence is a core tenet of Apyx Medical Corporation’s business model. The company emphasizes rigorous quality control processes during the design, development, and manufacturing phases of its products. Such practices ensure that every device meets stringent safety and performance criteria, a crucial factor in the highly regulated medical device industry. Through continuous process improvements and quality management systems, the company maintains a robust operational framework that supports its long-term sustainability and reliability as a technology provider. This commitment to excellence enhances trust among healthcare professionals and institutional partners alike.
Clinical and Surgical Applications
The practical applications of Apyx Medical Corporation’s technologies span a wide range of clinical and surgical environments. In cosmetic surgery, the Renuvion system offers a transformative approach to body contouring by providing controlled energy delivery tailored for precision and minimal invasiveness. Similarly, the J-Plasma system is engineered to meet the rigorous demands of hospital surgical procedures, ensuring that surgeons can achieve effective tissue modification with enhanced safety. The integration of clinical evidence into its product development process further confirms the efficacy of these applications, thereby fortifying the company’s reputation in the clinical community. This dual-application strategy not only broadens the market reach but also underscores the versatility and adaptability of the company’s technological solutions.
Strategic Collaborations and Market Expansion
Apyx Medical Corporation’s strategic approach includes forging key partnerships within the medical device sector through OEM arrangements. These collaborations facilitate the integration of its advanced energy technologies into the broader ecosystem of medical devices, thereby driving market expansion. By leveraging the expertise of established industry partners, the company is able to refine its product offerings, gain new insights into market demands, and maintain a competitive edge. Such collaborations ensure that Apyx remains at the cutting edge of medical technology innovation, thereby continuously reinforcing its value proposition.
Expertise and Authoritativeness
The company’s extensive experience and technical expertise in the field of energy-based surgical solutions are evident in its comprehensive portfolio and the clinical validation of its products. With a heritage rooted in decades of research and innovation, Apyx Medical Corporation has developed a robust framework for understanding and addressing the complex challenges inherent in both cosmetic and surgical treatments. This depth of expertise is reflected in the strategic development and deployment of its technologies, which combine precision engineering with a clear understanding of clinical needs. The company’s ability to deliver solutions that optimize surgical outcomes while minimizing risks highlights its authoritative presence in the energy technology space.
Competitive Landscape and Differentiation
Within a competitive market populated by several established players, Apyx Medical Corporation differentiates itself through its unique blend of advanced energy technology and strategic OEM partnerships. Its focus on precision, safety, and controlled heat delivery distinguishes its product offerings from traditional electrosurgical instruments. The company’s approach to integrating clinical evidence with innovative technology ensures that its solutions are both effective and reliable. This differentiation is critical in an industry where technological nuances can significantly impact surgical outcomes and patient safety. By continually investing in research and maintaining rigorous quality standards, Apyx positions itself as a trusted provider of cutting-edge medical technologies.
Conclusion
In summary, Apyx Medical Corporation exemplifies the convergence of energy technology and advanced medical device manufacturing. Its dual-segment operation, spanning both advanced energy products and OEM manufacturing, enables the company to offer comprehensive solutions that address critical needs in cosmetic and surgical applications. Through its innovative plasma-based systems, the company delivers unmatched precision and safety, supported by an extensive body of clinical research and a commitment to operational excellence. As a respected contributor to the energy technology and medical device industries, Apyx continues to influence the standard of care in surgical procedures, making it a subject of ongoing interest for investors, healthcare professionals, and industry analysts alike.
Apyx Medical (NASDAQ: APYX), developer of the proprietary Renuvion helium plasma and radiofrequency technology, has scheduled its Fourth Quarter and Fiscal Year 2024 financial results release for March 13, 2025, before market opening.
The company will host a conference call at 8:30 a.m. Eastern Time on the same day, featuring a management discussion and Q&A session. Interested parties can join via phone (877-407-9039 for domestic, 201-689-8470 for international) using access code 13751519, or through the company's webcast link and Investor Relations website section.
Apyx Medical specializes in advanced energy technology, particularly its Helium Plasma Platform Technology, marketed as Renuvion in cosmetic surgery and J-Plasma in hospital surgical markets. The company's products are supported by over 90 clinical documents and provide controlled heat tissue treatment.
Apyx Medical (NASDAQ:APYX) has released preliminary revenue results for Q4 and full year 2024. The company expects Q4 total revenue between $14.1-14.3 million, down 3-4% year-over-year, with Advanced Energy revenue of $12.0-12.2 million (flat YoY) and OEM revenue of $2.1 million (down 17% YoY).
For full year 2024, total revenue is projected at $48.0-48.2 million, an 8% decrease YoY. Advanced Energy segment expects $38.5-38.7 million (down 11% YoY), while OEM revenue shows growth at $9.5 million (up 6% YoY).
Notable improvements include 25% quarter-over-quarter growth in Advanced Energy sales during Q4, doubled generator unit sales in H2 2024 compared to H1, and strong U.S. single-use handpiece sales. The company plans to launch its new AYON™ Body Contouring System in H2 2025, pending FDA clearance, targeting the growing market for loose skin treatments, particularly driven by GLP-1 drug-related weight loss.
Apyx Medical (NASDAQ:APYX) has submitted a 510(k) premarket notification to the FDA for its AYON Body Contouring System, nearly 90 days ahead of schedule. The system is designed as an all-in-one platform for surgical body contouring procedures.
The initial submission includes multiple functionalities: infiltration, dual aspiration for simultaneous users, ultrasound-assisted liposuction, electrocoagulation for excess tissue removal, volume enhancement capabilities, and Renuvion treatment for loose and lax skin. The company plans to expand AYON's indications with an additional 510(k) submission later this year to include power-assisted liposuction.
Apyx Medical (NASDAQ:APYX) announced its participation in the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024, in New York. President and CEO Charlie Goodwin and CFO Matt Hill will conduct a fireside chat at 4:00pm ET and meet with investors throughout the day. The chat will be available via live webcast and replay on the company's investor relations website.
Apyx Medical specializes in advanced energy technology, particularly its Helium Plasma Platform Technology marketed as Renuvion® for cosmetic surgery and J-Plasma® for hospital surgical markets. These products provide controlled heat delivery to tissue, supported by over 90 clinical documents.
Apyx Medical (NASDAQ:APYX) announced that President and CEO Charles Goodwin and CFO Matt Hill will attend the 15th Annual Craig-Hallum Alpha Select Conference. The event will take place on November 19, 2024, at the Sheraton NY Times Square Hotel in New York, NY, featuring 1x1 meetings format.
Apyx Medical is an advanced energy technology company specializing in Helium Plasma Platform Technology products, marketed as Renuvion in cosmetic surgery and J-Plasma in hospital surgical markets. Their technology provides surgeons with controlled heat tissue treatment capabilities, supported by over 90 clinical documents.
Apyx Medical (NASDAQ:APYX) has secured a $7 million registered direct offering through a definitive purchase agreement with Nantahala Capital. The offering includes 3,000,000 shares of common stock at $1.18 per share and pre-funded warrants for up to 2,934,690 shares at $1.179 per warrant. The purchase price was calculated using the average closing price over five trading days prior to November 7, 2024. The company plans to use the proceeds for working capital and general corporate purposes. The offering closed on November 8, 2024, with no placement agent involved.
Apyx Medical reported Q3 2024 financial results with total revenue of $11.5 million, down 4% year-over-year. The company's Advanced Energy segment decreased 6% to $9.3 million, while OEM revenue increased 3% to $2.2 million. Despite overall decline, single-use handpiece revenue grew 9% overall and 15% in the U.S. The company secured $7.0 million through a registered direct offering and implemented cost-saving measures, including a 25% reduction in U.S. workforce expected to save $4.3 million annually. Updated 2024 guidance projects total revenue of $46.6-47.6 million, representing a 9-11% decrease from 2023, with net loss expected at approximately $25.0 million.
Apyx Medical (NASDAQ:APYX) announced it will release its third quarter fiscal year 2024 financial results before market opening on November 8th, 2024. The company will host a conference call at 8:00 a.m. Eastern Time on the same day, featuring a management discussion and Q&A session. The call will be accessible via phone (877-407-9039 for domestic, 201-689-8470 for international callers) with access code 13749764, and through a live webcast on the company's Investor Relations website.
Apyx Medical (NASDAQ: APYX) announced that Renuvion has been named the #1 trusted body contouring technology by doctors in an independent survey. This recognition highlights Renuvion's effectiveness in targeting loose skin for body contouring procedures. Key points include:
- Renuvion is the first and only technology targeting loose skin from the inside out
- 4 out of 5 surgeons prefer Renuvion over other treatments following liposuction
- Over 350,000 patients have been treated with Renuvion
- Apyx Medical has secured four FDA 510(k) clearances in the past two years
- Renuvion is the only FDA-cleared device for contracting subcutaneous tissue and for use after liposuction
This recognition underscores Apyx Medical's commitment to providing evidence-based outcomes through advanced technology in plastic surgery.
Apyx Medical (NASDAQ:APYX) announced the publication of a peer-reviewed study in Plastic and Reconstructive Surgery—Global Open comparing their Renuvion Helium Plasma Technology to InMode's Bipolar RF System following liposuction or body contouring procedures. The study, involving over 450 patients, found that Renuvion exhibited statistically significant fewer adverse events (p-value <0.0001) compared to Bipolar RF.
Key findings include:
- 45 adverse events in 34 Renuvion patients vs. 93 in 62 Bipolar RF patients
- 28 procedure-related events with Renuvion vs. 69 with Bipolar RF
- Significantly fewer burns, hematomas, hypertrophic scars, and seromas with Renuvion
Researchers concluded that Renuvion may offer a safer alternative with shorter procedural times and higher patient satisfaction rates.
FAQ
What is the current stock price of Apyx Medical Corporation (APYX)?
What is the market cap of Apyx Medical Corporation (APYX)?
What is Apyx Medical Corporation's core business?
How does Apyx generate revenue?
What are the main technologies used by Apyx Medical Corporation?
Who are the primary customers of Apyx Medical Corporation?
How does the company ensure the safety and efficacy of its products?
What differentiates Apyx Medical Corporation from its competitors?
In what ways does the company support clinical applications?
What role do OEM partnerships play for Apyx Medical Corporation?
